8-K: Spectral AI Secures $30 Million Equity Line with YA II PN, Ltd.

Spectral AI has entered into a standby equity purchase agreement with YA II PN, Ltd., providing access to up to $30 million in funding.

Summary

• Spectral AI has secured a standby equity purchase agreement (SEPA) with YA II PN, Ltd. for up to $30 million.
• The agreement includes a prepaid advance of $12.5 million, with $5 million funded immediately at a fixed conversion price of $3.16.
• The remaining $7.5 million of the prepaid advance will be disbursed in two tranches: $5 million upon the effectiveness of a registration statement or shareholder approval to exceed the Exchange Cap, and $2.5 million 60 days later.
• The prepaid advance will amortize over 7 months following a 45-day grace period, with monthly principal payments of $1.75 million plus a 7% premium.
• The investor has the option to convert the notes into shares at a fixed price or a variable price based on the VWAP.
• The company has the option to draw down additional funds at its discretion, up to the $30 million total.
• The SEPA replaces the company's existing committed equity facility.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the company's access to new capital and strategic initiatives. However, the potential for dilution and the terms of the financing agreement introduce some caution.

Positives

• The agreement provides Spectral AI with access to a significant amount of capital, up to $30 million.
• The initial $5 million tranche of the prepaid advance provides immediate funding.
• The company has flexibility in drawing down additional funds beyond the prepaid advance.
• The SEPA replaces the company's existing committed equity facility, potentially offering better terms.
• The funding supports the company's strategic imperatives and commercialization initiatives.

Negatives

• The prepaid advance includes an 8% original issue discount, reducing the net proceeds.
• The prepaid advance amortizes over 7 months, requiring significant monthly payments.
• The investor has the option to convert the notes into shares, potentially diluting existing shareholders.
• The company is subject to certain limitations on the number of shares it can issue under the agreement.

Risks

• The company's ability to draw down additional funds is subject to its discretion and market conditions.
• The conversion of notes into shares could lead to dilution of existing shareholders.
• The company is subject to certain limitations on the number of shares it can issue under the agreement.
• The company must maintain an effective registration statement to allow the investor to resell shares.
• The company must obtain shareholder approval to issue shares in excess of the Exchange Cap.

Future Outlook

The company expects that any proceeds received from sales to Yorkville will be used for working capital and general corporate purposes. The company is focused on clinical trials in the U.S., accelerating towards the commercialization of the diabetic foot ulcer indication and the burn indication.

Management Comments

• We are pleased to announce this equity funding as we pivot to commercialization while continuing our research and development activities, said Peter M. Carlson, CEO of Spectral AI.
• Together with our non-dilutive funding from various U.S. Government agencies, this new equity-linked instrument supports our strategic imperatives.

Industry Context

This agreement reflects a trend of biotech companies seeking flexible financing options to support research, development, and commercialization efforts. The use of a standby equity purchase agreement allows the company to access capital as needed, while also providing the investor with the potential for returns through share conversions.

Comparison to Industry Standards

• The use of a standby equity purchase agreement is a common financing method for small to mid-cap biotech companies, similar to companies like Athersys and Ocugen who have used similar structures.
• The terms of the agreement, including the prepaid advance, conversion prices, and amortization schedule, are within the typical range for such agreements.
• The 8% original issue discount is a standard feature of these types of financings, reflecting the risk taken by the investor.
• The fixed conversion price of $3.16 for the initial tranche is a premium to the current share price, which is a positive for the company.
• The variable conversion price, based on a discount to the VWAP, is a common feature designed to protect the investor from market fluctuations.

Stakeholder Impact

• Shareholders may experience dilution due to the potential conversion of notes into shares.
• Employees may benefit from the company's increased financial stability and growth prospects.
• Customers may benefit from the company's continued development and commercialization of its products.
• Creditors may benefit from the company's improved financial position.

Next Steps

• The company will file a registration statement with the SEC.
• The company will seek shareholder approval to issue shares in excess of the Exchange Cap.
• The company will continue to focus on clinical trials and commercialization efforts.
• The company will make monthly payments on the prepaid advance.

Key Dates

Keywords

standby equity purchase agreement, SEPA, convertible promissory notes, equity financing, YA II PN, Ltd., prepaid advance, share dilution, registration statement, commercialization, medical diagnostics, wound care, artificial intelligence